These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2413 related items for PubMed ID: 10363986

  • 1. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 2. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM, Béhé M, Löhr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W.
    Eur J Nucl Med; 2000 Jul 01; 27(7):753-65. PubMed ID: 10952487
    [Abstract] [Full Text] [Related]

  • 4. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.
    Cancer; 1997 Dec 15; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [Abstract] [Full Text] [Related]

  • 5. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov 15; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 6. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 Nov 15; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 7. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM, Béhé M, Sgouros G.
    Cancer Biother Radiopharm; 2002 Aug 15; 17(4):445-64. PubMed ID: 12396708
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL.
    Cancer Res; 1994 Aug 15; 54(16):4362-70. PubMed ID: 8044783
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
    Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM.
    Cancer Res; 1990 Apr 15; 50(8):2330-6. PubMed ID: 2180566
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC, Washburn LC, Sun TT, Byrd BL, Crook JE, Holloway EC, Steplewski Z.
    Cancer Res; 1990 Aug 01; 50(15):4546-51. PubMed ID: 2164441
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM, Kaltovich FA, Shih LB, Fand I, Govelitz G, Goldenberg DM.
    Cancer Res; 1988 Jun 01; 48(11):3270-5. PubMed ID: 3365705
    [Abstract] [Full Text] [Related]

  • 12. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 13. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
    Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA.
    Cancer Res; 1991 Apr 01; 51(7):1883-90. PubMed ID: 2004371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 20. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR.
    Cancer Res; 1994 Dec 01; 54(23):6176-85. PubMed ID: 7954464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 121.